Navigation Links
Medication does not lower risk of fungal infection, death among ELBW infants
Date:5/3/2014

Use of the antifungal medication fluconazole for six weeks for extremely low birth-weight infants did not significantly reduce the risk of death or invasive candidiasis, a serious infection that occurs when candida (a type of fungus) enters the bloodstream and spreads through the body, according to a study in the May 7 issue of JAMA, a theme issue on child health. This issue is being released early to coincide with the Pediatric Academic Societies Annual Meeting.

Invasive candidiasis is an important cause of infection in premature infants; despite treatment with antifungal therapy, invasive candidiasis has serious effects on premature infants, including severe neurodevelopmental impairment and death. Current recommendations include the use of fluconazole for prevention of this infection for infants with a birth weight of less than 1,000 grams (2.2 lbs.) who receive care in neonatal intensive care units (NICUs). However, most NICUs in the United States and the European Union have not uniformly adopted preventive use of fluconazole, based on controversies regarding high-risk patients, resistance, and safety, according to background information in the article.

Daniel K. Benjamin Jr., M.D., Ph.D., of Duke University, Durham, N.C., and colleagues evaluated the efficacy and safety of fluconazole in preventing death or invasive candidiasis in extremely low birth-weight infants (weighing less than 750 grams [1.7 lbs.] at birth). The study included 361 infants from 32 NICUs in the United States who were randomly assigned to receive either fluconazole (6mg/kg of body weight) or placebo twice weekly for 42 days.

The primary composite end point of death or invasive candidiasis by study day 49 was not statistically different between the 2 groups (fluconazole, 16 percent vs placebo, 21 percent). The percentage of infants who died prior to study day 49 was not different between the groups (14 percent vs 14 percent). Fewer infants developed definite or probable invasive candidiasis in the fluconazole (3 percent) vs in the placebo group (9 percent).

"Fluconazole prophylaxis compared with placebo was not associated with a statistically significant difference in the composite primary end pointdeath or definite or probable invasive candidiasis although it was associated with a statistically significant reduction in the incidence of definite or probable candidiasis alone. This study adds new evidence regarding the efficacy of fluconazole prophylaxis, but raises the question of whether prevention of invasive candidiasis translates into substantial improvements in the outcomes of prematurity."

"Based on both the results of our study in NICUs with a low incidence of invasive candidiasis, and previous prophylaxis trials in high-incidence NICUs, the routine use of fluconazole prophylaxis should be limited to units with moderate-to-high incidence of invasive candidiasis. However, additional research is needed to precisely define the incidence at which the benefits of fluconazole prophylaxis outweigh the risks," the authors write.


'/>"/>

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Nearly 50 percent of M.D.s believe diversion of ADHD stimulant medications among teens is a problem
2. UH Rainbow to study African-Americans response to asthma medications
3. HHS leaders call for expanded use of medications to combat opioid overdose epidemic
4. Medication does not help prevent ED following radiation therapy for prostate cancer
5. Medication does not reduce risk of recurrent CV events among patients with diabetes
6. Erectile dysfunction can be reversed without medication
7. Electronic medication alerts designed with provider in mind reduce prescribing errors
8. One in 5 older Americans take medications that work against each other
9. Anti-psychotic medications offer new hope in the battle against glioblastoma
10. Blood pressure medications given right after stroke not beneficial, study finds
11. MIT robot may accelerate trials for stroke medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of education, ... with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week Hackathon ... 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every organization ...
(Date:7/20/2017)... Falls Church, VA (PRWEB) , ... July 20, ... ... Improve Your Bottom Line, **An FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. ... a secret weapon to passing inspections and boosting quality. , It’s known as ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Business Architecture Guild® ... Knowledge (BIZBOK® Guide )v 6.0 is now available for member download. This release ... collaborative teams. , Non-members may download the Part 1 Introduction for free ...
(Date:7/20/2017)... ... July 19, 2017 , ... A local summer theatre ... funds raised to support fine arts programs in Chester County’s Elementary Schools. In ... University’s Loyd Auditorium. , More than 850 people attended the two performances, ...
(Date:7/20/2017)... ... 19, 2017 , ... Western University of Health Sciences College ... grant to train predoctoral dental students in providing care to vulnerable children ages ... , The Predoctoral Pediatric Training Project (PPTP), a five-year grant, recognizes the curriculum ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... July 10, 2017  The tenth annual BioPharm ... MA at the Sheraton Boston Hotel, September ... access to global decision makers and innovative biotech startup ... science leaders during two impactful days. BioPharm America is ... with additional networking opportunities with 4,500+ life science industry ...
(Date:7/5/2017)... of over 2,000 employees and a leader in environmental and life science testing, ... position as the top American owned and operated environmental testing firm in ... ... The ... , enhances Pace Analytical,s capability as an innovative full service provider in the ...
(Date:6/30/2017)... POINT, N.C. , June 29, 2017  Axium Pharmaceuticals Inc. ... for developing improved novel formulations and alternative dosage forms of ... ... delivery is based on our waterless self-nano emulsifying formula, which ... contact with saliva. We believe the spray will provide fast ...
Breaking Medicine Technology: